Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
- Author:
Zhan-Guo LI
1
;
Yi LIU
2
;
Hu-Ji XU
3
;
Zhi-Wei CHEN
4
;
Chun-De BAO
5
;
Jie-Ruo GU
6
;
Dong-Bao ZHAO
7
;
Yuan AN
1
;
Lie-Ju HWANG
8
;
Lisy WANG
9
;
Joel KREMER
10
;
Qi-Zhe WU
11
Author Information
- Publication Type:Journal Article
- Keywords: Clinical Efficacy; Patient-Reported Outcomes; Rheumatoid Arthritis; Safety; Tofacitinib
- MeSH: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; drug therapy; Asian Continental Ancestry Group; Female; Humans; Male; Middle Aged; Piperidines; adverse effects; therapeutic use; Protein Kinase Inhibitors; adverse effects; therapeutic use; Pyrimidines; adverse effects; therapeutic use; Pyrroles; adverse effects; therapeutic use; Surveys and Questionnaires; Young Adult
- From: Chinese Medical Journal 2018;131(22):2683-2692
- CountryChina
- Language:English
-
Abstract:
Background:Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This study assessed the efficacy and safety of tofacitinib in Chinese patients with RA enrolled in Phase 3 and long-term extension (LTE) studies.
Methods:ORAL Sync was a 1-year, randomized, placebo-controlled, Phase 3 trial. Patients received tofacitinib 5 or 10 mg twice daily (BID) or placebo advanced to tofacitinib 5 or 10 mg BID at 3 or 6 months. All patients remained on ≥1 background conventional synthetic disease-modifying antirheumatic drug. ORAL Sequel is an open-label LTE study (data-cut: March 2015; data collection and analyses were ongoing, and study database was not locked at the time of analysis; study was closed in 2017). Efficacy outcomes: American College of Rheumatology (ACR) 20/50/70 response rates and Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-4 [ESR]). Patient- and physician-reported outcomes: Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient and Physician Global Assessment of Arthritis, and pain (visual analog scale). Safety was assessed throughout.
Results:ORAL Sync included 218 patients; 192 were subsequently enrolled into ORAL Sequel. In ORAL Sync, more patients achieved ACR20 (tofacitinib 5 mg BID, 67.4%; 10 mg BID, 70.6%; placebo, 34.1%) and DAS28-4 (ESR) <2.6 (tofacitinib 5 mg BID, 7.1%; 10 mg BID, 13.1%; placebo, 2.3%) with tofacitinib versus placebo at Month 6. Mean changes from baseline in HAQ-DI were greater with tofacitinib versus placebo at Month 6. In ORAL Sequel, efficacy was consistent to Month 48. Incidence rates for adverse events of special interest in tofacitinib-treated patients were similar to the global population.
Conclusions:Tofacitinib significantly reduced signs/symptoms and improved physical function and quality of life in Chinese patients with moderate-to-severely active RA up to Month 48. The safety profile was consistent with the global population.
Clinical Trial Identifier:NCT00856544 and NCT00413699.
